MX2019010043A - Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-piperidin-1-il)-propenona. - Google Patents

Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-piperidin-1-il)-propenona.

Info

Publication number
MX2019010043A
MX2019010043A MX2019010043A MX2019010043A MX2019010043A MX 2019010043 A MX2019010043 A MX 2019010043A MX 2019010043 A MX2019010043 A MX 2019010043A MX 2019010043 A MX2019010043 A MX 2019010043A MX 2019010043 A MX2019010043 A MX 2019010043A
Authority
MX
Mexico
Prior art keywords
propenone
ylamino
piperidin
phenoxy
phenyl
Prior art date
Application number
MX2019010043A
Other languages
English (en)
Inventor
Becker Axel
Poma Marco
Burini Edoardo
Saal Christoph
Theuerkorn Vedad
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019010043A publication Critical patent/MX2019010043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una forma sólida de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pirimidin-4-ilamino]-metil}-pip eridin-1-il)-propenona, o sales farmacéuticamente aceptables de la misma, útiles como inhibidores de BTK.
MX2019010043A 2017-02-27 2018-02-27 Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-piperidin-1-il)-propenona. MX2019010043A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762463913P 2017-02-27 2017-02-27
US201762528238P 2017-07-03 2017-07-03
PCT/EP2018/054741 WO2018154131A1 (en) 2017-02-27 2018-02-27 Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone

Publications (1)

Publication Number Publication Date
MX2019010043A true MX2019010043A (es) 2019-09-26

Family

ID=61616961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010043A MX2019010043A (es) 2017-02-27 2018-02-27 Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-piperidin-1-il)-propenona.

Country Status (14)

Country Link
US (2) US10464923B2 (es)
EP (1) EP3585781A1 (es)
JP (2) JP2020509014A (es)
KR (1) KR102633267B1 (es)
CN (1) CN110662742A (es)
AU (1) AU2018223190B2 (es)
BR (1) BR112019017701A2 (es)
CA (1) CA3054464A1 (es)
IL (1) IL268928B2 (es)
MX (1) MX2019010043A (es)
NZ (1) NZ755922A (es)
SG (1) SG11201907836XA (es)
WO (1) WO2018154131A1 (es)
ZA (1) ZA201906361B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464923B2 (en) * 2017-02-27 2019-11-05 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone
US11878967B2 (en) * 2018-06-19 2024-01-23 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
KR20210034623A (ko) * 2018-07-20 2021-03-30 메르크 파텐트 게엠베하 다발성 경화증의 치료 및 예방을 위한 방법에서 사용하기 위한 치환된 아미노-피리미딘 화합물
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023280272A1 (zh) * 2021-07-07 2023-01-12 杭州领业医药科技有限公司 伊沃替尼和其盐的晶型及其制备方法和用途
WO2023285696A1 (en) 2021-07-15 2023-01-19 Sandoz Ag Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
CN115650955A (zh) * 2021-09-02 2023-01-31 都创(上海)医药开发有限公司 Evobrutinib化合物与糖精的共晶晶型及其制备方法
WO2023157030A1 (en) * 2022-02-21 2023-08-24 Msn Laboratories Private Limited, R&D Center Process for the preparation of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl) amino)methyl)piperidin-1-yl)prop-2-en-1-one
CN117986236A (zh) * 2022-11-07 2024-05-07 天津征程医药科技有限公司 氘代的嘧啶衍生物以及包含该化合物的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201801668WA (en) 2011-06-10 2018-03-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US10464923B2 (en) * 2017-02-27 2019-11-05 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone

Also Published As

Publication number Publication date
US10689363B2 (en) 2020-06-23
US20200017464A1 (en) 2020-01-16
SG11201907836XA (en) 2019-09-27
JP2023061941A (ja) 2023-05-02
EP3585781A1 (en) 2020-01-01
IL268928A (en) 2019-10-31
WO2018154131A1 (en) 2018-08-30
CN110662742A (zh) 2020-01-07
CA3054464A1 (en) 2018-08-30
IL268928B1 (en) 2023-04-01
BR112019017701A2 (pt) 2020-03-31
IL268928B2 (en) 2023-08-01
AU2018223190A1 (en) 2019-10-10
JP2020509014A (ja) 2020-03-26
NZ755922A (en) 2022-07-01
US20190010142A1 (en) 2019-01-10
ZA201906361B (en) 2021-02-24
KR20190123290A (ko) 2019-10-31
KR102633267B1 (ko) 2024-02-05
AU2018223190B2 (en) 2021-09-23
US10464923B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
MX2019010043A (es) Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-piperidin-1-il)-propenona.
MX2022007432A (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino.
MX2017014108A (es) Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-ilox i) metilo) ciclopropanamina, su forma cristalina y sus sales.
LT3577110T (lt) 8-oksetan-3-il-3,8-diazabiciklo[3.2.1]oktan-3-ilo pakeistieji junginiai, kaip živ inhibitoriai
MY197700A (en) Compounds useful for inhibiting cdk7
MX2019011759A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando el mismo.
MX2020013321A (es) Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtencion.
MX2013010360A (es) Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos.
PH12015500275A1 (en) Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
WO2017160116A3 (ko) 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물
MX368125B (es) Metodos para producir compuestos sulfilimina.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
IL267303B (en) Method for the production of -7-(3,4-dichloro-2-fluorophenylamino)-4)-4)-1 methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
MX2018001517A (es) Derivados sustituidos de guanidina.
WO2018127612A3 (en) Compositions comprising lespedeza plant extract
IN2014MU00455A (es)
MX2018006329A (es) Agente terapeutico para cancer de mama.
AU2018326785A1 (en) Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
MX2021002875A (es) Formas cristalinas de un compuesto de quinazolina y sus sales clorhidrato.
MX2019001763A (es) Metodo para preparar derivados de estireno sustituidos.
EP3348549A4 (en) METHODS FOR RESPECTIVELY PRODUCING A 2,4,6-TRIS (2-HYDROXY-3-METHYL-4-ALCOXYPHENYL) -1,3,5-TRIAZINE COMPOUND AND A 2,4,6-TRIS COMPOUND (2,4- dIHYDROXY-3-methylphenyl) -1,3,5-TRIAZINE
EA201991977A1 (ru) Новые кристаллические формы 1-(4-{[6-амино-5-(4-феноксифенил)пиримидин-4-иламино]метил}пиперидин-1-ил)пропенона